Evidence map›Paper›PMID 40322852›Full record

ArticleArthritis care & research2025

Carpal Tunnel Syndrome as an Early Underrecognized Feature of Rheumatoid Arthritis: A Population-Based Study of Carpal Tunnel Syndrome Occurrence Before and After Rheumatoid Arthritis Incidence.

Roslin Jose George, Noah Frechette, Manuela Oviedo, Iqra Javed, Sara J Achenbach, Ryan J Lennon, Bradley Alex Kimbrough, Elena K Joerns, Vanessa L Kronzer, Anne Gingery and 3 more

Abstract read
In one paragraph

Article in Arthritis care & research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Roslin Jose GeorgeMayo Clinic, Rochester, Minnesota.
Noah FrechetteMayo Clinic, Rochester, Minnesota.
Manuela OviedoMayo Clinic, Rochester, Minnesota.
Iqra JavedMayo Clinic, Rochester, Minnesota.
Sara J AchenbachMayo Clinic, Rochester, Minnesota.
Ryan J LennonMayo Clinic, Rochester, Minnesota.
Bradley Alex KimbroughMayo Clinic, Rochester, Minnesota.
Elena K JoernsMayo Clinic, Rochester, Minnesota.
Vanessa L KronzerMayo Clinic, Rochester, Minnesota.ORCID 0000-0002-7489-3134
Anne GingeryMayo Clinic, Rochester, Minnesota.ORCID 0000-0002-1690-7382
John M DavisMayo Clinic, Rochester, Minnesota.ORCID 0000-0002-9710-8143
Cynthia S CrowsonMayo Clinic, Rochester, Minnesota.ORCID 0000-0001-5847-7475
Elena MyasoedovaMayo Clinic, Rochester, Minnesota.ORCID 0000-0003-2006-1436

Funding

HEART DISEASE IN RHEUMATOID ARTHRITISR01AR046849 · NIAMS · MAYO CLINIC ROCHESTER · PI CROWSON, CYNTHIA S · 2000 to 2022
$11.3M
Musculoskeletal Research Training ProgramT32AR056950 · NIAMS · MAYO CLINIC ROCHESTER · PI Jennifer J Westendorf · 2009 to 2026
$7.0M
Role of Systemic Inflammation in Cognitive Decline: Rheumatoid Arthritis as a PrototypeR01AG068192 · NIA · MAYO CLINIC ROCHESTER · PI Elena Myasoedova · 2020 to 2026
$4.4M
The Role of Cellular Senescence in Carpal Tunnel Syndrome.R01AR076347 · NIAMS · MAYO CLINIC ROCHESTER · PI Anne Gingery · 2020 to 2026
$3.3M
Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology ProjectR33AG058738 · NIA · MAYO CLINIC ROCHESTER · PI LEBRASSEUR, NATHAN K, OLSON, JANET E · 2020 to 2022
$2.4M
Population-Based Outcomes Research for Rheumatoid Arthritis: Rural Health DisparitiesR01AR084831 · NIAMS · MAYO CLINIC ROCHESTER · PI Cynthia S Crowson · 2024 to 2026
$2.4M
Temporal associations between systemic inflammation, cardiovascular risk profile and development of Alzheimer’s disease and related dementias in patients with rheumatoid arthritisK24AG078179 · NIA · MAYO CLINIC ROCHESTER · PI Elena Myasoedova · 2022 to 2026
$951k
Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology ProjectR21AG058738 · NIA · MAYO CLINIC ROCHESTER · PI LEBRASSEUR, NATHAN K, OLSON, JANET E · 2018 to 2019
$437k
Population-Based Outcomes Research for Rheumatoid Arthritis: Rural Health DisparitiesR56AR046849 · NIAMS · MAYO CLINIC ROCHESTER · PI CROWSON, CYNTHIA S · 2023 to 2023
$150k
NIAMS NIH HHS R01 AR046849NIAMS NIH HHS R01 AR076347NIAMS NIH HHS R01 AR084831NIAMS NIH HHS R01 AR46849NIAMS NIH HHS R56 AR046849NIAMS NIH HHS T32 AR056950NIA NIH HHS K24 AG078179NIA NIH HHS R01 AG058738NIA NIH HHS R01 AG068192NIA NIH HHS R21 AG058738NIA NIH HHS R33 AG058738
6 · The paper itself

Abstract

objectiveWe aimed to assess the occurrence of carpal tunnel syndrome (CTS) before and after rheumatoid arthritis (RA) incidence and by serologic status.

methodsThis population-based study included residents of a geographically defined area meeting the 1987 American College of Rheumatology classification criteria for RA in 1980 to 2019 matched 1:1 with individuals without RA. At least two diagnosis codes ≥30 days apart were used to identify CTS. Cumulative incidence of CTS adjusting for competing risk of death was assessed. Logistic regression and Cox proportional hazard models were used, adjusting for age, sex, calendar year, smoking, obesity, diabetes mellitus, and hypothyroidism.

resultsWe included 1,335 patients with RA and 1,331 individuals without RA. The overall prevalence of CTS before or on RA incidence or index was 179 patients with RA (13%) and 85 individuals without RA (6%), respectively (odds ratio [OR] 2.23; 95% confidence interval [CI] 1.69-2.94). Most previous incidences of CTS occurred ≥2 years before the index date (112 events in patients with RA and 75 events in individuals without RA, respectively). Following RA incidence or index, individuals with RA (vs those without RA) had ~80%-higher risk of CTS (hazard ratio [HR] 1.78; 95% CI 1.38-2.30). The risk estimates of CTS in patients with seronegative (vs seropositive) RA were OR 1.33 (95% CI 0.96-1.84) before RA incidence and HR 1.37 (95% CI 0.99-1.88) after RA incidence. In RA, obesity (HR 1.42, 95% CI 1.02-1.99) and seronegative cyclic citrullinated peptide antibody status (HR 1.79, 95% CI 1.07-2.99), but not other risk factors, were associated with increased CTS risk.

conclusionWe found a more than two-fold increase in risk of CTS in the years preceding RA and a 1.8-fold increased risk of incident CTS following RA onset.

Indexed as

Arthritis, RheumatoidCarpal Tunnel SyndromeAdultAgedAnti-Citrullinated Protein AntibodiesFemaleHumansIncidenceMaleMiddle AgedPrevalenceRisk FactorsTime FactorsAnti-Citrullinated Protein Antibodies

Identifiers

PMID40322852
PMCPMC12353601

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.